Jasper Therapeutics (JSPR) Short-Term Debt issuances (2022)
Jasper Therapeutics (JSPR) posted quarterly Short-Term Debt issuances of -$57000.0 for Q2 2022, down 105.04% quarter-over-quarter from $1.1 million in Q1 2022.
Jasper Therapeutics (JSPR) Short-Term Debt issuances (2022) Analysis & Trends
Jasper Therapeutics' Short-Term Debt issuances history runs 1 years deep, the most recent figure standing at -$57000.0 for Q2 2022.
- In Q2 2022, Short-Term Debt issuances changed N/A year-over-year to -$57000.0; the TTM figure through Dec 2022 stood at $1.1 million (changed N/A YoY), while the FY2022 annual figure was $1.1 million, changed N/A from the prior year.
- Short-Term Debt issuances for Q2 2022 stood at -$57000.0, down from $1.1 million in the prior quarter.
- The five-year high for Short-Term Debt issuances was $1.1 million in Q1 2022, with the low at -$57000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -57,000.00 |
| Jun 30, 2022 | -57,000.00 |
| Mar 31, 2022 | 1.13 Mn |
| Mar 31, 2022 | 1.13 Mn |